title: [The non-hormonal treatment of metastatic prostate cancer].
abstract: OBJECTIVE
  To describe drugs used in the non-hormonal treatment of metastatic prostate cancer.
  
  
  METHODS
  Bibliographical search was performed from the database Medline (National Library of Medicine, PubMed) and websites of the HAS and the ANSM. The search was focused on the characteristics, the mode of action, the efficiency and the side effects of the various drugs concerned.
  
  
  RESULTS
  The metabolic radiotherapy although under-used for this indication, kept a place at the beginning of the disease. Radium-223 chloride seems to have to occupy an important place in the coming years. The chemotherapy, the only recourse until very recently in the castration-resistant prostate cancer, must redefine its place partially. The denosumab provide an interesting alternative to bisphosphonates.
  
  
  CONCLUSIONS
  The non-hormonal treatment of the metastatic disease of the prostate cancer is changing rapidly with the emergence of new molecules. Urologist must know perfectly these new drugs.
authors.affiliation: Service d'urologie, hôpital Saint-Louis, AP-HP, université Paris 7-Denis-Diderot, 75010 Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Mongiat-Artus
authors.forename: I
authors.initials: I
authors.lastname: Brenot-Rossi
authors.forename: P
authors.initials: P
authors.lastname: Beuzeboc
authors.forename: F
authors.initials: F
authors.lastname: Bruyère
authors.forename: G
authors.initials: G
authors.lastname: Karsenty
authors.forename: L
authors.initials: L
authors.lastname: Guy
authors.forename: C
authors.initials: C
authors.lastname: Bastide
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D002945:Cisplatin / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D000069448:Denosumab; D000077143:Docetaxel; D005047:Etoposide / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008942:Mitoxantrone / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D009943:Organophosphorus Compounds / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D010024:Osteoporosis / Q000209:etiology / Q000517:prevention & control; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*; D053245:RANK Ligand / Q000037:antagonists & inhibitors; D011835:Radiation Protection / Q000379:methods; D011868:Radioisotopes / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D011883:Radium / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D013324:Strontium / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D013326:Strontium Radioisotopes / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D043823:Taxoids / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D053245:RANK Ligand; D011868:Radioisotopes; D013326:Strontium Radioisotopes; D043823:Taxoids; D000077143:Docetaxel; D000069448:Denosumab; C552428:cabazitaxel; D005047:Etoposide; C061972:samarium Sm-153 lexidronam; D008942:Mitoxantrone; C025700:strontium chloride; D002945:Cisplatin; C581106:radium Ra 223 dichloride; D011883:Radium; D013324:Strontium
keywords: Bisphosphanates; Bisphosphonates; Cancer de la prostate; Chemotherapy; Chimiothérapie; Denosumab; Dénosumab; Metabolic radiotherapy; Metastatic castration-resistant prostate cancer; Métastases; Prostate cancer; RANK-Ligand; Radiothérapie métabolique; Résistant à la castration